![T-cell destroys cancer cell digital animation.jpg](https://static.wixstatic.com/media/4995e2_7f6365ef2d8c4c8584574216b09da943~mv2.jpg/v1/fill/w_102,h_102,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_avif,quality_auto/4995e2_7f6365ef2d8c4c8584574216b09da943~mv2.jpg)
![T-cell destroys cancer cell digital animation.jpg](https://static.wixstatic.com/media/4995e2_7f6365ef2d8c4c8584574216b09da943~mv2.jpg/v1/fill/w_123,h_123,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_avif,quality_auto/4995e2_7f6365ef2d8c4c8584574216b09da943~mv2.jpg)
ImmunoACT, an IIT-Bombay spin-off incubated at SINE, is India's first gene-modified cell therapy company, fully integrated from R&D to Manufacturing and Commercialization.
Our goal is bringing innovative, affordable and accessible cell & gene therapies to the masses, to improve overall survival outcomes in diseases with a clinically unmet need.
India ranks second in global cancer mortality
![Screenshot 2021-08-02 20_edited.png](https://static.wixstatic.com/media/854f5b_56fd0402a2cd4da5b7993c0ed6e39a93~mv2.png/v1/crop/x_0,y_99,w_250,h_217/fill/w_189,h_164,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/Screenshot%202021-08-02%2020_edited.png)
In B-cell cancers such as Acute Lymphoblastic Leukaemia & Large B-cell Lymphomas, over 40% of patients do not achieve a response to first line therapies or relapse.
CAR-T Cell Therapies are a revolution in the care of haematological malignancies, showing remarkable improvements in overall & disease-free survival rates.
* Based on inputs from multiple centres in India
![Microscope](https://static.wixstatic.com/media/11062b_e77c099a7a2a4a0fbccdf519c0a0114f~mv2.jpeg/v1/fill/w_123,h_81,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_avif,quality_auto/11062b_e77c099a7a2a4a0fbccdf519c0a0114f~mv2.jpeg)
Our Technology
We design, develop, and manufacture novel therapies called CARs (Chimeric Antigen Receptors), which are created by modifying a patient's own T-cells by using a vehicle that enables them to better target certain cancers and enhance their anti-tumour activity.
Our CAR-T cell therapies, beginning with NexCAR19 (Talicabtagene autoleucel) are personalized for each patient, and are specifically designed to be more familiar to the human immune system, limiting their side-effects and rendering them safer.
What are CAR-T Cell Therapies?
![car-t-stock-graphic-1440.jpg](https://static.wixstatic.com/media/4995e2_729aa615a0c74ca4b517bc6e7057dc4c~mv2.jpg/v1/fill/w_106,h_48,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_avif,quality_auto/4995e2_729aa615a0c74ca4b517bc6e7057dc4c~mv2.jpg)
By using a specially designed and patented delivery vehicle called a Lentiviral Vector, T-cells (a set of immune system cells present in our bodies with natural tumour-fighting abilities) are modified - so that they can express proteins which will target specific cancers and enhance their anti-tumour activity against these cancers.
CAR-T Cell Therapies involve training your immune cells to actively and aggressively target known signals on certain types of cancers - and to save these abilities in their memory for future use.
Recoveries are the strongest motivation
Stories from patients who have received NexCAR19 (Talicabtagene autoleucel) in their fight against cancer:
Our Location
1st Floor, Plot R-977, TTC Industrial Area, MIDC Rabale, Navi Mumbai, India – 400701
Contact Number
+91 2248259140